

# United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

| APPLICATION NO.  | FILING DATE          | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO.     | CONFIRMATION NO |  |
|--|----------------------|----------------------|-------------------------|-----------------|--|
| 10/696,708   | 10/30/2003           | Mark T. Keating      | 2323-164                | 7822            |  |
| 6449   | 7590 04/21/2006      |                      | EXAMINER                |                 |  |
| ROTHWELL, FIGG, ERNST & MANBECK, P.C.<br>1425 K STREET, N.W. |                      |                      | QIAN, CELINE X          |                 |  |
| SUITE 800  | EI, N.W.             |                      | ART UNIT                | PAPER NUMBER    |  |
| WASHINGTO  | WASHINGTON, DC 20005 |                      |                         | 1636            |  |
|  |                      |                      | DATE MAILED: 04/21/2006 | 5               |  |

Please find below and/or attached an Office communication concerning this application or proceeding.

|  | Application No.  | Applicant(s)  |  |  |  |  |
|--|--|---|--|--|--|--|
|  | 10/696,708   | KEATING ET AL.  |  |  |  |  |
| Office Action Summary  | Examiner   | Art Unit  |  |  |  |  |
|  | Celine X. Qian Ph.D.   | 1636  |  |  |  |  |
| The MAILING DATE of this communication Period for Reply  | appears on the cover sheet with the  | correspondence address  |  |  |  |  |
| A SHORTENED STATUTORY PERIOD FOR RI WHICHEVER IS LONGER, FROM THE MAILIN  - Extensions of time may be available under the provisions of 37 CF after SIX (6) MONTHS from the mailing date of this communication.  If NO period for reply is specified above, the maximum statutory pr  - Failure to reply within the set or extended period for reply will, by soon any reply received by the Office later than three months after the rearned patent term adjustment. See 37 CFR 1.704(b). | G DATE OF THIS COMMUNICATIO<br>FR 1.136(a). In no event, however, may a reply be tin.<br>eriod will apply and will expire SIX (6) MONTHS from<br>statute, cause the application to become ABANDONE | N. mely filed n the mailing date of this communication. ED (35 U.S.C. § 133). |  |  |  |  |
| Status   |  |   |  |  |  |  |
| 1) Responsive to communication(s) filed on _   |  |   |  |  |  |  |
|  | This action is non-final.  |   |  |  |  |  |
| <i>'</i> =   | Since this application is in condition for allowance except for formal matters, prosecution as to the merits is  |   |  |  |  |  |
| ·  | closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.  |   |  |  |  |  |
| Disposition of Claims  |  |   |  |  |  |  |
| 4)⊠ Claim(s) <u>5-10</u> is/are pending in the application.  |  |   |  |  |  |  |
| 4a) Of the above claim(s) is/are withdrawn from consideration.   |  |   |  |  |  |  |
| 5) Claim(s) is/are allowed.  |  |   |  |  |  |  |
| 6)⊠ Claim(s) <u>5-10</u> is/are rejected.  | ☑ Claim(s) 5-10 is/are rejected.   |   |  |  |  |  |
| 7) Claim(s) is/are objected to.  | Claim(s) is/are objected to.   |   |  |  |  |  |
| 8) Claim(s) are subject to restriction a   | nd/or election requirement.  |   |  |  |  |  |
| Application Papers   |  |   |  |  |  |  |
| 9) The specification is objected to by the Example 1   | miner.   |   |  |  |  |  |
| 10)⊠ The drawing(s) filed on <u>30 October 2003</u> is/are: a)⊠ accepted or b)□ objected to by the Examiner.   |  |   |  |  |  |  |
| Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  |  |   |  |  |  |  |
| Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).   |  |   |  |  |  |  |
| 11)☐ The oath or declaration is objected to by th  | e Examiner. Note the attached Office   | e Action or form PTO-152.   |  |  |  |  |
| Priority under 35 U.S.C. § 119   |  |   |  |  |  |  |
| 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:   |  |   |  |  |  |  |
| <ol> <li>Certified copies of the priority documents have been received.</li> </ol>   |  |   |  |  |  |  |
| 2. Certified copies of the priority documents have been received in Application No   |  |   |  |  |  |  |
| 3. Copies of the certified copies of the   | priority documents have been receive   | ed in this National Stage   |  |  |  |  |
| application from the International Bu  | ,  |   |  |  |  |  |
| * See the attached detailed Office action for a  | a list of the certified copies not receiv  | ed.   |  |  |  |  |
|  |  |   |  |  |  |  |
| Attachment(s)  |  |   |  |  |  |  |
| 1) Notice of References Cited (PTO-892)  | 4) Interview Summar  |   |  |  |  |  |
| <ul> <li>2) Notice of Draftsperson's Patent Drawing Review (PTO-948</li> <li>3) Information Disclosure Statement(s) (PTO-1449 or PTO/S</li> </ul>  |  | Patent Application (PTO-152)  |  |  |  |  |
| Paper No(s)/Mail Date <u>0504</u> . 6) Other:  |  |   |  |  |  |  |

Application/Control Number: 10/696,708

Art Unit: 1636

### **DETAILED ACTION**

Claims 5-10 are pending in the application.

#### Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

I-XVIII, Claims 5-10, drawn to a method for detecting a mutation which causes or is associated with LQT syndrome by amplifying one of exons 1-15 of HERG using a pair of primers SEQ ID NO: 56-95, classified in class 536, subclass 24.33.

Groups I-XVIII are comprised of multiple inventions which are the methods drawn to using different and distinct pair of primer sequences which do not render obvious each other and thus are patentably distinct. Applicants must elect a single invention which is the method drawn to one specific pair of sequences to which the claims will be restricted. Note, this restriction to examination of a single sequence is due to the now very high and undue burden for examining more than one sequence which is caused by the continued exponential increase of size of the sequence databases to be searched for each sequence, resulting in a corresponding increase in computer search time and examiner time for reviewing the computer search results. Therefore, the limited resources of the Office no longer permit examination of more than one sequence in an application.

During a telephone conversation with Applicant's representative on 4/6/06 a provisional election was made with traverse to prosecute the invention of Group III, claims 5-10. (SEQ ID NO: 60 and 61). Affirmation of this election must be made by applicant in replying to this Office action.

# Claim Objections

Claims 6, 8 and 10 are objected to because of they contain non-elected subject matter.

Claim 6 recites SEQ ID NO: 56-95, only SEQ ID NO: 60 and 61 are elected for examination at present. Appropriate correction is required.

## Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 5, 7 and 9 are rejected under 35 U.S.C. 102(b) as being anticipated by Keating et al (US 5,599,673, 1997).

The claims are drawn to a method of identifying a mutation which causes or associates with long QT syndrome by amplifying one of exons 1-15 of HERG with a pair of primers that amplifies the entire exon, and analyzing the amplified exon with a mutation. The claims are further drawn to such a method, wherein the analyzing step is carried out by SSNP or sequencing the amplified exon.

Keating et al. disclose a method of identifying a mutation which causes or associates with long QT syndrome by amplifying one of exons 1-15 of HERG with a pair of primers that amplifies the entire exon, and analyzing the amplified exon with a mutation (see col.33, line 13, through col.34, line 60). Keating et al. further discloses that the mutation is identified by SSNP or sequencing the amplified exon (see col. 32, lines 52-53, and lines 58-59). Therefore, Keating et al. disclose the instantly claimed invention.

Application/Control Number: 10/696,708

Art Unit: 1636

## **Double Patenting**

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPO 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 5-10 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 3-8, 10, 15 and 16 of U.S. Patent No. US 6,207,383. Although the conflicting claims are not identical, they are not patentably distinct from each other because the claims of the '383 patent are drawn to methods of detecting mutation in HERG using the same primers. Therefore, they anticipate the currently claimed invention.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Celine X. Qian Ph.D. whose telephone number is 571-272-0777. The examiner can normally be reached on 9:30-6:00 M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Remy Yucel Ph.D. can be reached on 571-272-0781. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/696,708 Page 5

Art Unit: 1636

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Celine X Qian Ph.D. Examiner Art Unit 1636

CELINE QIAN, PH.D. PRIMARY EXAMINER